| Chemical Properties | Back Directory | [Boiling point ]
540.230±60.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.504±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [pka]
-2.478±0.10(predicted) |
| Hazard Information | Back Directory | [Uses]
WYJ-2 is a selective agonist for toll-like receptor 2/1 (TLR2/1) with EC50 of 18.57 nM in human TLR2 and TLR1 transient-cotransfected HEK 293T cells. WYJ-2 induces pyroptosis and exhibits anticancer activity against non-small cell lung cancer (NSCLC)[1]. | [in vivo]
WYJ-2 (5 mg/kg, i.p. every teo days for 30 days) inhibits tumor growth without significant toxicity in A549 xenograft BALB/c mice[1].
WYJ-2 (10 mg/kg, i.p.) exhibits a pharmacokinetic profil with half-time of T1/2 of 3.67 h and a clearance Cmax of 497 ± 49 ng/mL[1]. | Animal Model: | A549 xenograft BALB/c mice[1] | | Dosage: | 5 mg/kg | | Administration: | i.p. every two days for 30 days | | Result: | Inhibited tumor growth with a TGI of 72.22% without significant loss of body weight. |
| [IC 50]
TLR2 | [References]
[1] Wang Y, et al., Design and Synthesis of 3-(2H-Chromen-3-yl)-5-aryl-1,2,4-oxadiazole Derivatives as Novel Toll-like Receptor 2/1 Agonists That Inhibit Lung Cancer In Vitro and In Vivo. J Med Chem. 2024 Mar 18. DOI:10.1021/acs.jmedchem.3c01984 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|